AccScience Publishing

Innovative Medicines & Omics (IMO) is a peer-reviewed and open-access journal that publishes articles on the critical analysis of human health and animal medicine-related original omics research and its applications in innovative medicines.

The journal includes a variety of omics layers, such as genomics, proteomics, epigenomics metabolomics, lipidomics, peptidomics, metagenomics, microbiome, pharmacogenomics, toxicogenomics, etc., with the focus on disease etiology, prevention, treatment, prognosis and monitoring.

Features include original research articles, reviews, short communications and editorials. Topics of particular interest include, but are not limited to:

Disease evolution and heterogeneity
Single-cell sequencing technique
Circulating tumor cell
Personalized medicine
Drug sensitivity screening
Combination therapy
Drug resistance
Disease therapeutic mechanism and marker detection
Database and web server
Computational method
Assisted reproduction
Embryonic development
Animal organ regeneration
Bioproduct and biomaterial
Novel therapeutic strategies
High-throughput screening
Therapeutic targets
Combinatorial chemistry, parallel synthesis and library design
Drug delivery
Advances in key compound classes and therapeutic areas
Automation and technology

2. Ownership

The journal is owned by Accscience Publishing and co-organized with China Optimization and Development Association (CODA).

3. Publishing Model

Gold open access. All articles published by IMO are made freely and permanently accessible online immediately from the date of publication. For further information, please refer to Open Access.

4. Copyright and License to Publish

License

Articles in IMO are published under a Creative Commons Attribution 4.0 International (CC BY 4.0). The CC BY 4.0 allows for maximum dissemination and re-use of open access materials and is preferred by many research funding bodies. Under this license users are free to share (copy, distribute and transmit) and remix (adapt) the contribution for any purposes, even commercially, provided that the users appropriately acknowledge the original authors and the source.

5. Editorial Board

For more information about the editorial team, please refer to Editorial Board.

6. Editorial Policies

All manuscripts submitted to IMO should adhere to AccScience Publishing's Editorial Policies.

7. Manuscript Processing System

ASP serves a diverse global community of scholars, committed to freely sharing cutting-edge research under the Creative Commons Attribution (CC BY) license. To enhance the precision, academic rigor, and timeliness of our publications, we have developed the proprietary, cutting-edge manuscript processing system known as the OSS (Online Submission System).

8. Peer Review

The journal adheres to rigorous peer review and undergoes double-blind peer review. For more details, please refer to Editorial Process.

9. Publication Ethics Statement

IMO fully adheres to the Code of Conduct and the Best Practice Guidelines of Committee on Publication Ethics (COPE).

The Editors of this journal enforce a rigorous peer-review process together with strict ethical policies and standards to guarantee to add high quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data falsification, image manipulation, inappropriate authorship credit, and the like, do arise. The Editors of IMO take such publishing ethics issues very seriously and are trained to proceed in such cases with a zero tolerance policy. To verify the originality of content submitted to our journals, we use CrossCheck (powered by iThenticate) to check submissions against previous publications.

10. Journal Information and Statistics

Print ISSN: 3060-8910
Frequency: Quarterly

Digital archive: Portico

11. Contact

Please visit the page of Editorial Office for details about different queries.

Innovative Medicines & Omics, Electronic ISSN: 3060-8740 Print ISSN: 3060-8910, Published by AccScience Publishing